Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Diep HoJessica HuangJudith-Anne W ChapmanKim LeitzelSuhail M AliLois ShepherdWendy R ParulekarCatherine E EllisRocco J CrescnzoLiting ZhuShakeel VirkDora NomikosSamuel AparicioKaren A GelmonWalter P CarneyAllan LiptonPublished in: Breast cancer research and treatment (2017)
Higher levels of serum TIMP-1, CAIX, and HER2 were significant prognostic biomarkers of shorter PFS. We found no significant interaction between serum biomarkers and response to lapatinib versus trastuzumab. Evaluation of TIMP-1 and CAIX-targeted therapy in addition to HER2-targeted therapy appears warranted in patients with elevated serum levels of these biomarkers.